Novel Helicobacter pylori therapeutic targets: The unusual suspects

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 7, 2009, Pages 835-867

  Duckworth, Megan J ^a   Okoli, Arinze S ^a   Mendz, George L ^a  

^a UNIVERSITY OF NOTRE DAME   (Australia)

Author keywords

Antibacterials; Essential genes; Essential proteins; Helicobacter pylori; Host colonization; Therapeutic targets

Indexed keywords

3 DEHYDROQUINATE DEHYDRATASE; ALPHA 1,3 FUCOSYLTRANSFERASE; AMOXICILLIN; ANTIBIOTIC AGENT; CARBONATE DEHYDRATASE; CLARITHROMYCIN; CYSTATHIONINE GAMMA LYASE; DIHYDROOROTATE DEHYDROGENASE; FLAGELLIN; FLAVODOXIN; FUMARATE REDUCTASE; METRONIDAZOLE; OROTATE PHOSPHORIBOSYLTRANSFERASE; PALMITOYL COENZYME A HYDROLASE; PROTON PUMP INHIBITOR; SHIKIMIC ACID; SPERMIDINE SYNTHASE; SUPEROXIDE DISMUTASE; THIOREDOXIN REDUCTASE; UREASE; URIDINE DIPHOSPHATE GLUCOSE 4 EPIMERASE;

BACTERIAL COLONIZATION; BACTERIAL GENETICS; BACTERIAL GROWTH; BACTERIAL SURVIVAL; DRUG TARGETING; DYSPEPSIA; ERADICATION THERAPY; HELICOBACTER INFECTION; HUMAN; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NONHUMAN; REVIEW; STOMACH CANCER; STOMACH ULCER;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; GENE EXPRESSION REGULATION, BACTERIAL; GENES, BACTERIAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MICE;

EID: 70350641519     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/ERI.09.61     Document Type: Review

References (249)

1. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE Jr. Trends in antimicrobial drug development: implications for the future. Clin. Infect. Dis. 38, 1279-1286 (2004). (Pubitemid 38608571)
2. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 42, 657-668 (2006). (Pubitemid 43271379)
3. Norrby SR, Nord CE, Finch R. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect. Dis. 5, 115-119 (2005). (Pubitemid 40174782)
4. Hoppe-Seyler F, Butz K. Peptide aptamers: powerful new tools for molecular medicine. J. Mol. Med. 78, 426-430 (2000). (Pubitemid 30809272)
5. Fang G, Rocha E, Danchin A. How essential are nonessential genes? Mol. Biol. Evol. 22, 2147-2156 (2005). (Pubitemid 41437796)
6. Mushegian A. The minimal genome concept. Curr. Opin. Genet. Dev. 9, 709-714 (1999).
7. Legrain P, Strosberg D. Protein interaction domain mapping for the selection of validated targets and lead compounds in the anti-infectious area. Curr. Pharm. Des. 8, 1189-1198 (2002). (Pubitemid 34594249)
8. Sarker SA, Mahalanabis D, Hildebrand P et al. Helicobacter pylori: prevalence, transmission, and serum pepsinogen II concentrations in children of a poor periurban community in Bangladesh. Clin. Infect. Dis. 25, 990-995 (1997). (Pubitemid 27513172)
9. Bassily S, Frenck RW, Mohareb EW et al. Seroprevalence of Helicobacter pylori among Egyptian newborns and their mothers: a preliminary report. Am. J. Trop. Med. Hyg. 61, 37-40 (1999). (Pubitemid 29344984)
10. Forman D, Graham DY. Review article: impact of Helicobacter pylori on society-role for a strategy of 'search and eradicate'. Aliment. Pharmacol. Ther. 19(Suppl. 1), 17-21 (2004).
11. Malfertheiner P, Megraud F, O'Morain C et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56, 772-781 (2007). (Pubitemid 46854190)
12. Covacci A, Telford JL, Del Giudice G, Parsonnet J, Rappuoli R. Helicobacter pylori virulence and genetic geography. Science 284, 1328-1333 (1999). (Pubitemid 29289653)
13. Reszka E, Jegier B, Wasowicz W, Lelonek M, Banach M, Jaszewski R. Detection of infectious agents by polymerase chain reaction in human aortic wall. Cardiovasc. Pathol. 17, 297-302 (2008).
14. Najafizadeh K, Falah Tafti S, Shiehmorteza M, Saloor M, Jamali M. H. pylori seroprevalence in patients with lung cancer. World J. Gastroenterol. 13, 2349-2351 (2007). (Pubitemid 46860737)
15. Suzuki T, Matsushima M, Shirakura K et al. Association of inflammatory cytokine gene polymorphisms with platelet recovery in idiopathic thrombocytopenic purpura patients after the eradication of Helicobacter pylori. Digestion 77, 73-78 (2008). (Pubitemid 351556383)
16. Ito K, Yamaoka Y, Ota H, El-Zimaity H, Graham DY. Adherence, internalization, and persistence of Helicobacter pylori in hepatocytes. Dig. Dis. Sci. 53, 2541-2549 (2008).
17. Karaer A, Ozkan O, Ozer S et al. Gastrointestinal symptoms and Helicobacter pylori infection in early pregnancy. A seroepidemiologic study. Gynecol. Obstet. Invest. 66, 44-46 (2008). (Pubitemid 352009130)
18. Li W, Minohara M, Su JJ et al. Helicobacter pylori infection is a potential protective factor against conventional multiple sclerosis in the Japanese population. J. Neuroimmunol. 184, 227-231 (2007). (Pubitemid 46366004)
19. Moyaert H, Franceschi F, Roccarina D, Ducatelle R, Haesebrouck F, Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection: other Helicobacters. Helicobacter 13(Suppl. 1), 47-57 (2008). (Pubitemid 47312377)
20. Cavallaro LG, Egan B, O'Morain C, Di Mario F. Treatment of Helicobacter pylori infection. Helicobacter 11(Suppl. 1), 36-39 (2006).
21. Vaira D, Zullo A, Vakil N et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann. Intern. Med. 146, 556-563 (2007). (Pubitemid 351650536)
22. Vakil N, Vaira D. Sequential therapy for Helicobacter pylori: time to consider making the switch? JAMA 300, 1346-1347 (2008).
23. Leontiadis GI, Sreedharan A, Dorward S et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol. Assess. 11, 1-164 (2007).
24. Fukase K, Kato M, Kikuchi S et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 372, 392-397 (2008).
25. Salama NR, Shepherd B, Falkow S. Global transposon mutagenesis and essential gene analysis of H. pylori. J. Bacteriol. 186, 7926-7935 (2004). • Transposon insertion was employed to determine genes that are essential to the survival of Helicobacter pylori. Independent verification of the essentiality of several gene products was performed.
26. Chalker AF, Minehart HW, Hughes NJ et al. Systematic identification of selective essential genes in H. pylori by genome prioritisation and allelic replacement mutagenesis. J. Bacteriol. 183, 1259-1268 (2001). •• A comparative genomic approach was employed to identify H. pylori 26695 genes conserved in H. pylori J99 and that highly diverged in other eubacteria. A survey of selected pathways of central intermediary metabolism was also performed, and genes with a potentially essential role in H. pylori were identified.
27. Baldwin DN, Shepherd B, Kraemer P et al. Identification of H. pylori genes contributing to stomach colonisation. Infect. Immun. 75, 1005-1016 (2006). •• The C57BL/6 mouse model of infection was utilized to query 2400 transposon mutants in two different bacterial strain backgrounds for H. pylori genetic loci contributing to colonization of the stomach.
28. Kavermann H, Burns BP, Angermuller K et al. Identification and characterisation of H. pylori genes essential for gastric colonisation. J. Exp. Med. 197, 813-822 (2003). •• A set of previously unknown H. pylori factors necessary for gastric colonization and pathogenesis were identified using the Mongolian gerbil as a model system to screen a set of 960 signature-tagged mutants.
29. Loughlin MF. Novel therapeutic targets in H. pylori. Expert Opin. Therap. Targets. 7, 725-735 (2003). •• Reviews how genomic, proteomic and transcriptomic data to determine essential gene products as targets for novel therapeutic agents can be obtained, evaluated and eventually used as a basis for the development of both vaccine and novel anti-Helicobacter agents.
30. Akada JK, Ogura K, Dailidiene D, Dailide G, Cheverud JM, Berg DE. H. pylori tissue tropism: mouse-colonising strains can target different gastric niches. Microbiology 149, 1901-1909 (2003).
31. Bury-Mone S, Mendz GL, Ball GE et al. Roles of a and b carbonic anhydrases of H. pylori in the urease-dependent response to acidity and in colonisation of the murine gastric mucosa. Infect. Immun. 76, 497-509 (2008). (Pubitemid 351251719)
32. Tomb JF, White O, Kerlavage AR et al. The complete genome sequence of the gastric pathogen H. pylori. Nature 388, 539-547 (1997).
33. Alm RA, Ling LS, Moir DT et al. Genomicsequence comparison of two unrelated isolates of the human gastric pathogen H. pylori. Nature 397, 176-180 (1999).
34. Oh JD, Kling-Backhed H, Glannakis M et al. The complete genome sequence of a chronic atrophic gastritis H. pylori strain: evolution during disease progression. Proc. Natl Acad. Sci. USA 103, 9999-10004 (2006). (Pubitemid 43993612)
35. Boneca IG, de Reuse H, Epinat JC, Pupin M, Labigne A, Moszer I. A revised annotation and comparative analysis of H. pylori genomes. Nucleic Acids Res. 31, 1704-1714 (2003). (Pubitemid 36336572)
36. Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 28, 27-30 (2000). (Pubitemid 30047706)
37. Han YH, Liu WZ, Shi YZ et al. Comparative genomics profiling of clinical isolates of H. pylori in Chinese populations using DNA microarray. J. Microbiol. 45, 21-28 (2007). •• Shows the use of whole genomic DNA microarray to characterize the genomic diversity of H. pylori strains isolated from clinical patients and concludes that clinical strains have extensive genomic diversity. The method may help select relatively significant genes for further development of a vaccine against H. pylori.
38. Gressmann H, Linz B, Ghai R et al. Gain and loss of multiple genes during evolution of H. pylori. PLoS Genet. 1, 419-428 (2005).
39. Salama N, Guillemin K, McDaniel TK, Sherlock G, Tompkins L, Falkow S. A whole-genome microarray reveals genetic diversity among H. pylori strains. Proc. Natl Acad. Sci. USA 97, 14668-14673 (2000). (Pubitemid 32016633)
40. Takeuchi H, Shirai M, Akada JK, Tsuda M, Nakazawa T. Nucleotide sequence and characterisation of cdrA, a cell division-related gene of H. pylori. J. Bacteriol. 180, 5263-5268 (1998). (Pubitemid 28470961)
41. Haas G, Karaali G, Ebermayer K et al. Immunoproteomics of H. pylori infection and relation to gastric disease. Proteomics 2, 313-324 (2002). (Pubitemid 34269985)
42. Kimmel B, Bosserhoff A, Frank R, Gross R, Goebel W, Beier D. Identification of immunodominant antigens from H. pylori and evaluation of their reactivities with sera from patients with different gastroduodenal pathologies. Infect. Immun. 68, 915-920 (2000). (Pubitemid 30056553)
43. Graham JE, Peek RM Jr, Krishna U, Cover TL. Global analysis of H. pylori gene expression in human gastric mucosa. Gastroenterology 123, 1637-1648 (2002). (Pubitemid 35231663)
44. Huynen M, Dandekar T, Bork P. Differential genome analysis applied to the species-specific features of H. pylori. FEBS Lett. 426, 1-5 (1998). (Pubitemid 28198144)
45. Stingl K, Uhlemann EM, Deckers-Habestreit G, Schmid R, Bakker EP, Altendorf K. Prolonged survival and cytoplasmic pH homeostasis of H. pylori at pH 1. Infect. Immun. 69, 1178-1181 (2001). (Pubitemid 32109588)
46. Bauerfeind P, Garner R, Dunn BE, Mobley HL. Synthesis and activity of H. pylori urease and catalase at low pH. Gut 40, 25-30 (1997). (Pubitemid 27079746)
47. Sachs G, Weeks DL, Wen Y, Marcus EA, Scott DR, Melchers K. Acid acclimation by H. pylori. Physiology 20, 429-438 (2005).
48. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat. Rev. Drug Discov. 7, 168-181 (2008).
49. Pope AJ, Toseland CDN, Rushant B, Richardson S, McVey M, Hills J. Effect of potent urease inhibitor, fluorofamide, on Helicobacter sp. in vitro and in vivo. Dig. Dis. Sci. 43, 109-119 (1998). (Pubitemid 28081650)
50. Houimel M, Mach JP, Corthesy-Theulaz I, Corthesy B, Fisch I. New inhibitors of H. pylori urease holoenzyme selected from phage-displayed peptide libraries. Eur. J. Biochem. 262, 774-780 (1999). (Pubitemid 29291035)
51. Hifumi E, Hatiuchi K, Okuda T, Nishizono A, Okamura Y, Uda T. Specific degradation of H. pylori urease by a catalytic antibody light chain. FEBS J. 272, 4497-12505 (2005).
52. Ikeda Y, Fujii R, Ogino K, Fukushima K, Hifumi E, Uda T. Immunological features and inhibitory effects on enzymatic activity of monoclonal antibodies against H. pylori urease. J. Ferm. Bio. 86, 271-276 (1998).
53. Rajinikanth PS, Mishra B. Preparation and in vitro characterisation of gellan based floating beads of acetohydroxamic acid for eradication of H. pylori. Acta Pharm. 57, 413-427 (2007).
54. Tanaka T, Kawase M, Tani S. α-hydroxyketones as inhibitors of urease. Bioorg. Med. Chem. 12, 501-505 (2004).
55. Mishra H, Parrill AL, Williamson JS. Three-dimensional quantitative structure-activity relationship and comparative molecular field analysis of dipeptide hydroxamic acid H. pylori urease inhibitors. Antimicrob. Agents Chemother. 46, 2613-2618 (2002). (Pubitemid 34793472)
56. Muri EMF, Mishra H, Avery MA, Williamson JS. Design and synthesis of heterocyclic hydroxamic acid derivatives as inhibitors of H. pylori urease. Synth. Comm. 33, 1977-1995 (2003).
57. Muri EMF, Mishra H, Stein SM, Williamson JS. Molecular modeling, synthesis and biological evalutation of heterocyclic hydroxamic acids designed as H. pylori urease inhibitors. Lett. Drug Des. Dis. 1, 30-34 (2004).
58. Panayiota Aristoteli L, O'Rourke JL, Danon S et al. Urea, flurofamide, and omeprazole treatments alter Helicobacter colonisation in the mouse gastric mucosa. Helicobacter 11, 460-468 (2006). (Pubitemid 44352618)
59. Hifumi E, Morihara F, Hatiuchi K, Okuda T, Nishizono A, Uda T. Catalytic features and eradication ability of antibody light-chain UA15-L against H. pylori. J. Biol Chem. 283, 899-907 (2008). •• Explains the development of a catalytic antibody capable of degrading the active site of the urease of H. pylori and eradicating the bacterial infection in a mouse stomach. This is the first example of a monoclonal catalytic antibody capable of functioning in vivo.
60. Zhang L, Mulrooney SB, Leung AFK et al. Inhibition of urease by bismuth(III): implications for the mechanism of action of bismuth drugs. BioMetals 19, 503-511 (2006). (Pubitemid 44291043)
61. Ge R, Sun X, Gu Q et al. A proteomic approach for the identification of bismuth-binding proteins in H. pylori. J. Biol. Inorg. Chem. 12, 831-842 (2007). (Pubitemid 47174873)
62. Han C, Wang L, Yu K et al. Biochemical characterisation and inhibitor discovery of shikimate dehydrogenase from H. pylori. FEBS J. 273, 4682-4692 (2006). (Pubitemid 44506909)
63. Cheng WC, Chang YN, Wang WC. Structural basis for shikimate-binding specificity of H. pylori shikimate kinase. J. Bacteriol. 187, 8156-8163 (2005).
64. Han C, Zhang J, Chen L, Chen K, Shen X, Jiang H. Discovery of H. pylori shikimate kinase inhibitors: bioassay and molecular modelling. Bioorg. Med. Chem. 15, 656-662 (2007). (Pubitemid 44895506)
65. Angelini A, Cendron L, Goncalves S, Zanotti G, Terradot L. Structural and enzymatic characterisation of Hp0496, a YbgC thioesterase from H. pylori. Proteins 72, 1212-1221 (2008).
66. Gln. J. Biol. Chem. 282, 11866-11873 (2007).
67. Asn and novel aminoacyl-tRNA analogues are competitive inhibitors. Biochemistry 46, 13190-13198 (2007).
68. Balg C, Huot JL, Lapointe J, Chenervert R. Inhibition of H. pylori animoacyl-tRNA amidotransferase by puromycin analogues. J. Am. Chem. Soc. 130, 3264-3265 (2008).
69. Han C, Wang Q, Dong L et al. Molecular cloning and characterisation of a new peptide deformylase from human pathogenic bacterium H. pylori. Biochem. Biophys. Res. Comm. 319, 1292-1298 (2004). (Pubitemid 38759551)
70. Gigilone C, Pierre M, Melnnel T. Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents. Mol. Microbiol. 36, 1197-1205 (2000). (Pubitemid 30449958)
71. Apfel CM, Locher H, Evers S et al. Peptide deformylase as an antibacterial drug target: target validation and resistance development. Antimicrob. Agents Chemother. 45, 1058-1064 (2001). (Pubitemid 32230983)
72. Fritsche TR, Sader HS, Cleeland R, Jones RN. Comparative antimicrobial characterisation of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance. Antimicrob. Agents Chemother. 49, 1468-1476 (2005). (Pubitemid 40463378)
73. Cai J, Han C, Hu T et al. Peptide deformylase is a potential target for anti-H. pylori drugs: reverse docking, enzymatic assay, and X-ray crystallography validation. Protein Sci. 15, 2071-2081 (2006). (Pubitemid 44316010)
74. McDaniel TK, Dewalt KC, Salama NR, Falkow S. New approaches for validation of lethal phenotypes and genetic reversion in H. pylori. Helicobacter. 6, 15-23 (2001). (Pubitemid 32601680)
75. Schar J, Sickmann A, Beier D. Phosphorylation-independent activity of atypical response regulators of H. pylori. J. Bacteriol. 187, 3100-3109 (2005). (Pubitemid 40571603)
76. Panthel K, Dietz P, Haas R, Beier D. Two-component systems of H. pylori contribute to virulence in a mouse infection model. Infect. Immun. 71, 5381-5385 (2003). (Pubitemid 37070788)
77. Beier D, Frank R. Molecular characterisation of two-component systems of H. pylori. J. Bacteriol. 182, 2068-2076 (2000). (Pubitemid 30183523)
78. Delany I, Spohn G, Rappuoli R, Scarlato V. Growth phase-dependent regulation of target gene promoters for binding of the essential orphan response regulator Hp1043 of H. pylori. J. Bacteriol. 184, 4800-4810 (2002). (Pubitemid 34898268)
79. Hong E, Lee HM, Ko H et al. Structure of an atypical orphan response regulator protein supports a new phosphorylationin-dependent regulatory mechanism. J. Biol. Chem. 282, 20667-20675 (2007). (Pubitemid 47099998)
80. Freigang J, Diederichs K, Schafer KP, Welte W, Paul R. Crystal structure of oxidised flavodoxin, an essential protein in H. pylori. Protein Sci. 11, 253-261 (2002). (Pubitemid 34075788)
81. Kwon DH, El-Zaatari FAK, Kato M et al. Analysis of rdxA and involvement of additional genes encoding NAD(P)H flavin oxidoreductase (FrxA) and ferredoxin-like protein (FdxB) in Metronidazole resistance of H. pylori. Antimicrob. Agents Chemother. 44, 2133-2142 (2000).
82. Backert S, Gressmann H, Kwok T et al. Gene expression and protein profiling of AGS gastric epithelial cells upon infection with H. pylori. Proteomics 5, 3902-3918 (2005). (Pubitemid 41502487)
83. Martinez-Julvez M, Cremades N, Bueno M et al. Common conformational changes in flavodoxins induced by FMN and anion binding: the structures of H. pylori apoflavodoxin. Proteins 69, 581-594 (2007). (Pubitemid 47623873)
84. Cremades N, Bueno M, Toja M, Sancho J. Towards a new therapeutic target: H. pylori flavodoxin. Biophys. Chem. 115, 267-276 (2005). • Provides an example of a potential target not present in the human host. Because H. pylori fladoxin has peculiar characteristics not found in other known flavodoxins, inhibition of its activity could allow the design of very specific anti-Helicobacter drugs.
85. Baker LMS, Raudonikiene A, Hoffman PS, Poole LB. Essential thioredoxin-dependent peroxiredoxin system for H. pylori: genetic and kinetic characterisation. J. Bacteriol. 183, 1961-1973 (2001).
86. Gustafsson TN, Sandalova T, Lu J, Holmgren A, Schneider G. High-resolution structures of oxidised and reduced thioredoxin reductase from H. pylori. Acta Crystallogr. D Biol. Crystallogr. 63, 833-843 (2007). (Pubitemid 46975673)
87. Zawilak-Pawlik A, Kois A, Stingl K et al. HobA - a novel protein involved in initiation of chromosomal replication in H. pylori. Mol. Microbiol. 65, 979-994 (2007). (Pubitemid 47221087)
88. Natrajan G, Hall DR, Thompson AC, Gutsche I, Terradot L. Structural similarity between the DnaA-binding proteins HobA (Hp1230) from H. pylori and DiaA from E. coli. Mol. Microbiol. 65, 995-1005 (2007). (Pubitemid 47221078)
89. Wen Y, Marcus EA, Matrubutham U, Gleeson MA, Scott DR, Sachs G. Acid-adaptive genes of H. pylori. Infect. Immun. 71, 5921-5939 (2003).
90. Tsai JY, Chen BT, Cheng HC et al. Crystal structure of Hp0242, a hypothetical protein from H. pylori with a novel fold. Proteins. 62, 1138-1143 (2006).
91. McAtee CP, Lim MY, Fung K et al. Identification of potential diagnostic and vaccine candidates of H. pylori by two-dimensional gel electrophoresis, sequence analysis, and serum profiling. Clin. Diagn. Lab. Immunol. 5, 537-542 (1998). (Pubitemid 28342884)
92. Moran AP, Sturegard E, Sjunnesson H, Wadstrom T, Hynes SO. The relationship between O-chain expression and colonisation ability of H. pylori in a mouse model. FEMS Immunol. Med. Microbiol. 29, 263-270 (2000).
93. Kwon DH, Woo JS, Perng CL, Go MF, Graham DY, El-Zaatari FAK. The effect of galE gene inactivation on lipopolysaccharide profile of H. pylori. Curr. Microbiol. 37, 144-148 (1998).
94. Edwards NJ, Monteiro MA, Faller G et al. Lewis X structure in the O antigen side-chain promote adhesion of H. pylori to the gastric epithelium. Mol. Microbiol. 35, 1530-1539 (2000). (Pubitemid 30175527)
95. Andermann TM, Chen YT, Ottemann KM. Two predicted chemoreceptors of H. pylori promote stomach infection. Infect. Immun. 70, 5877-5881 (2002).
96. Cerda O, Rivas A, Toledo H. H. pylori strain ATCC700392 encodes a methyl-accepting chemotaxis receptor protein (MCP) for arginine and sodium bicarbonate. FEMS Microbiol. Lett. 224, 175-181 (2003). (Pubitemid 36929822)
97. Wu JJ, Sheu BS, Huang AH, Lin ST, Yang HB. Characterisation of flgK gene and FlgK protein required for H. pylori colonisation - from cloning to clinical relevance. World J. Gastroenterol. 12, 3989-3993 (2006).
98. Kong Y, Wu D, Bai H et al. Enzymatic characterisation and inhibitor discovery of a new cystathionine g-synthase (CGS) from H. pylori. J. Biochem. 143, 59-68 (2008). (Pubitemid 351197714)
99. Sun HY, Lin SW, Ko TP et al. Structure and mechanism of H. pylori fucosyltransferase: a basis for lipopolysaccharide variation and inhibitor design. J. Biol. Chem. 282, 9973-9982 (2007).
100. Wang G, Rasko DA, Sherburne R, Taylor DE. Molecular genetic basis for the variable expression of Lewis Y antigen in H. pylori: analysis of the α(1,2) fucosyltransferase gene. Mol. Microbiol. 31, 1265-1274 (1999). (Pubitemid 29082254)
101. Lundqvist T, Fisher SL, Kern G et al. Exploitation of structural and regulatory diversity in glutamate racemases. Nature 447, 817-822 (2007). • Characterizes the glutamate racemases of several pathogenic bacteria using structural and biochemical approaches, and identifies a series of uncompetitive inhibitors specifically targeting Helicobacter pylori glutamate racemase that provide a basis for designing narrow-spectrum antimicrobial agents.
102. Censini S, Lange C, Xiang Z et al. cag, a pathogenicity island of H. pylori, encodes type I-specific and disease-associated virulence factors. Proc. Natl Acad. Sci. USA 93, 14648-14653 (1996). (Pubitemid 26419022)
103. Noonan B, Alm RA. Novel intervention strategies for H. pylori treatment. Curr. Drug Targets Infect. Disord. 2, 331-338 (2002). (Pubitemid 35446266)
104. Lu PK, Tsai JY, Chien HY, Huang H, Chu CH, Sun YJ. Crystal structure of H. pylori spermidine synthase: a rossman-like fold with a distinct active site. Proteins. 67, 743-754 (2007). (Pubitemid 46625589)
105. Lundstrom AM, Bolin I. A 26 kDa protein of H. pylori shows alkyl hydroperoxide reductase (AhpC) activity and the mono-cistronic transcription of the gene is affected by pH. Microb. Pathog. 29, 257-266 (2000). (Pubitemid 30945001)
106. Olczak AA, Olson JW, Maier RJ. Oxidative-stress resistance mutants of H. pylori. J. Bacteriol. 184, 3186-3193 (2002).
107. Croxen MA, Ernst PB, Hoffman PS. Antisense RNA modulation of alkyl hydroperoxide reductase (AhpC) levels in H. pylori correlates with organic peroxide toxiciy but not infectivity J. Bacteriol. 189, 3359-3368 (2007).
108. Marcinkeviciene J, Rogers MJ, Kopcho L et al. Selective inhibition of bacterial dihydroorotate dehydrogenases by thiadiazolidinediones. Biochem. Pharmacol. 60, 339-342 (2000). (Pubitemid 30336630)
109. Haque TS, Tadesse S, Marcinkeviciene J et al. Parallel synthesis of potent, pyrazole-based inhibitors of H. pylori dihydroorotate dehydrogenase. J. Med. Chem. 45, 4669-4678 (2002).
110. Copeland RA, Marcinkeviciene J, Haque TS et al. H. pylori-selective antibacterials based on inhibition of pyrimidine biosynthesis. J. Biol. Chem. 275, 33373-33378 (2000). (Pubitemid 30808546)
111. Campo SM, Zullo A, Hassan C, Morini S. Antibiotic treatment strategies for Helicobacter pylori infection. Recent Pat. Anti Infect. Drug Discov. 2(1), 11-17 (2007). (Pubitemid 46723156)
112. Payne D, Bush K. Casting a broader net for approaches to antibacterial research and development. Editorial overview. Curr. Opin. Biotechnol. 19(6), 606-607 (2008).
113. McNamara D, El-Omar E. Helicobacter pylori infection and the pathogenesis of gastric cancer: a paradigm for host-bacterial interactions. Dig. Liver Dis. 40(7), 504-509 (2008).
114. Conway BR. Drug delivery strategies for the treatment of Helicobacter pylori infections. Curr. Pharm. Des. 11(6), 775-790 (2005).
115. Lee SY, Shin YW, Hahm KB. Phytoceuticals: mighty but ignored weapons against Helicobacter pylori infection. J. Dig. Dis. 9(3), 129-139 (2008).
116. De Reuse H, Labigne A, Mengin-Lecreulx D. The H. pylori ureC gene codes for a phosphoglucosamine mutase. J. Bacteriol. 179, 3488-3493 (1997). (Pubitemid 27232984)
117. Dutta A, Singh SK, Ghosh P, Mukherjee R, Mitter S, Bandyopadhyay D. In silico identification of potential therapeutic targets in the human pathogen H. pylori. In Silico Biol. 6, 43-47 (2006). • Uses a subtractive genomics approach to identify a small subset of the Helicobacter proteome that could be investigated further for identifying potential drug and vaccine targets.
118. 0-ATPase from H. pylori. Infect. Immun. 65, 2640-2647 (1997).
119. Tsuda M, Karita M, Golam Morshed M, Okita K, Nakazawa T. A urease negative mutant of H. pylori constructed by allelic exchange mutagenesis lacks the ability to colonise the nude mouse stomach. Infect. Immun. 62, 3586-3589 (1994). (Pubitemid 24232155)
120. Snelling WJ, Moran AP, Ryan KA et al. HorB (Hp0127) is a gastric epithelial cell adhesin. Helicobacter 12, 200-209 (2007).
121. Ge Z, Feng Y, Dangler CA, Xu S, Taylor NS, Fox JG. Fumarate reductase is essential for H. pylori colonisation of the mouse stomach. Microb. Pathog. 29, 279-287 (2000). (Pubitemid 30945003)
122. Guo BP, Mekalanos JJ. Rapid genetic analysis of H. pylori gastric mucosal colonisation in suckling mice. Proc. Natl Acad. Sci. USA 99 8354-8359 (2002).
123. Seyler Jr RW, Olson JW, Maier RJ. Superoxide dismutase-deficient mutants of H. pylori are hypersensitive to oxidative stress and defective in host colonisation. Infect. Immun. 69, 4034-4040 (2001).
124. Eaton KA, Suerbaum S, Josenhans C, Krakowka S. Colonisation of gnotobiotic piglets by H. pylori deficient in two flagellin genes. Infect. Immun. 64, 2445-2448 (1996). (Pubitemid 26226803)
125. Kim JS, Chang JH, Chung SI, Yum JS. Molecular cloning and characterisation of the H. pylori fliD gene, an essential factor in flagellar structure and motility. J. Bacteriol. 181, 6969-6976 (1999).
126. Stahler FN, Odenbreit S, Haas R et al. The novel H. pylori CznABC metal efflux pump is required for cadmium, zinc, and nickel resistance, urease modulation and gastric colonisation. Infect. Immun. 74, 3845-3852 (2006). (Pubitemid 43993315)
127. Foynes S, Dorrell N, Ward SJ et al. Functional analysis of the roles of FliQ and FlhB in flagellar expression in H. pylori. FEMS Microbiol. Lett. 174, 33-39 (1999). (Pubitemid 29179430)
128. Clyne M, Ocroinin T, Suerbaum S, Josenhans C, Drumm B. Adherence of isogenic flagellum-negative mutants of H. pylori and H. mustelae to human and ferret gastric epithelial cells. Infect. Immun. 68, 4335-4339 (2000). (Pubitemid 30434593)
129. Stahler FN, Ganter L, Lederer K, Kist M, Bereswill S. Mutational analysis of the H. pylori carbonic anhydrases. FEMS Immunol. Med. Microbiol. 44, 183-189 (2005). (Pubitemid 41373375)
130. Marcus EA, Moshfegh AP, Sachs G, Scott DR. The periplasmic α-carbonic anhydrase activity of H. pylori is essential for acid acclimation. J. Bacteriol. 187, 729-738 (2005). (Pubitemid 40096259)
131. Nishimori I, Vullow D, Minakuchi T et al. Carbonic anhydrase inhibitors: cloning and sulfonamide inhibition studies of a carboxyterminal truncated α-carbonic anhydrase from H. pylori. Bioorg. Med. Chem. 16, 2182-2188 (2006). (Pubitemid 43351075)
132. Nishimori I, Minakuchi T, Kohsaki T et al. Carbonic anhydrase inhibitors: the β-carbonic anhydrase from H. pylori is a new target for sulfonamide and sulfamate inhibitors. Bioorg. Med. Chem. Lett. 17, 3585-3594 (2007). (Pubitemid 46898819)
133. Jarvinen N, Maki M, Rabina J, Roos C, Mattila P, Renkonen R. Cloning and expression of H. pylori GDP-L-fucose synthesizing enzymes (GMD and GMER) in S. cerevisiae. Eur. J. Biochem. 268, 6458-6464 (2001). (Pubitemid 34014753)
134. Wu B, Zhang Y, Wang PG. Identification and characterisation of GDP-D-mannose 4,6-dehydratase and GDP-L-fucose synthetase in a GDP-L-fucose biosynthesis gene cluster from H. pylori. Biochem. Biophys. Res. Commun. 285, 364-371 (2001). (Pubitemid 32918079)
135. Eaton KA, Krakowka S. Effect of gastric pH on urease-dependent colonisation of gnotobiotic piglets by H. pylori. Infect. Immun. 62, 3604-3607 (1994). (Pubitemid 24264297)
136. Mehta N, Benoit S, Maier RJ. Roles of conserved nucleotide-binding domains in accessory proteins, HypB and UreG, in the maturation of nickel-enzymes required for efficient H. pylori colonisation. Microb. Pathog. 35, 229-234 (2003). (Pubitemid 37163723)
137. Benoit SL, Mehta N, Weinberg MV, Maier C, Maier RJ. Interaction between the H. pylori accessory proteins HypA and UreE is needed for urease maturation. Microbiology 153, 1474-1482 (2007). (Pubitemid 46780003)
138. Benoit S, Maier RJ. Dependence of H. pylori urease activity on the nickel-sequestering ability of the UreE accessory protein. J. Bacteriol. 185, 4787-4795 (2003). (Pubitemid 36962286)
139. Skouloubris S, Thiberge JM, Labigne A, De Reuse H. The H. pylori UreI protein is not involved in urease activity but is essential for bacterial survival in vivo. Infect. Immun. 66, 4517-4521 (1998). (Pubitemid 28402735)
140. Mollenhauer-Rektorschek M, Hanauer G, Sachs G, Melchers K. Expression of UreI is required for intragastric transit and colonisation of gerbil gastric mucosa by H. pylori. Res. Microbiol. 153, 659-666 (2002). (Pubitemid 35449269)
141. Boonjakuakul JK, Syvanen M, Suryaprasad A, Bowlus CL, Solnick JV. Transcription profile of H. pylori in the human stomach reflects its physiology in vivo. J. Infect. Dis. 190, 946-956 (2004). (Pubitemid 39120972)
142. Weeks DL, Sachs G. Sites of pH regulation of the urea channel of H. pylori. Mol. Microbiol. 40, 1249-1259 (2001). (Pubitemid 32635296)
143. Scott DR, Marcus EA, Weeks GL, Lee A, Melchers K, Sachs G. Expression of the H. pylori ureI gene is required for acidic pH activation of cytoplasmic urease. Infect. Immun. 68, 470-477 (2000). (Pubitemid 30056496)
144. Weeks DL, Eskandari S, Scott DR, Sachs G. A H+-gated urea channel: the link between H. pylori urease and gastric colonisation. Science. 287, 482-485 (2000). (Pubitemid 33595255)
145. Gu Q, Han N, Liu J, Zhu M. Cloning of H. pylori urease subunit B gene and its expression in tobacco (Nicotiana tabacum L.). Plant Cell Rep. 24, 532-539 (2005). (Pubitemid 41531541)
146. Labigne A, Cussac V, Courcoux P. Shuttle cloning and nucleotide sequences of H. pylori genes responsible for urease activity. J. Bacteriol. 173, 1920-1931 (1991).
147. Kather B, Stingl K, van der Rest ME, Altendorf K, Molenaar D. Another unusual type of citric acid cycle enzyme in H. pylori: the malate:quinone oxidoreductase. J. Bacteriol. 182, 3204-3209 (2000). (Pubitemid 30326937)
148. Homuth G, Domm S, Kleiner D, Schumann W. Transcription analysis of major heat shock genes of H. pylori. J. Bacteriol. 182, 4257-4263 (2000). (Pubitemid 30465652)
149. Park SA, Lee HW, Hong MH et al. Comparative proteomic analysis of H. pylori strains associated with iron deficiency anemia. Proteomics 6, 1319-1328 (2006).
150. Wang G, Alamuri P, Maier RJ. The adverse antioxidant systems of H. pylori. Mol. Microbiol. 61, 847-860 (2006). • Elucidates the roles of all of these antioxidant systems by a targeted mutant analysis approach and shows their importance in host colonization. Some of the described antioxidant systems in H. pylori are potential therapeutic targets.
151. Wang G, Olczak AA, Walton JP, Maier RJ. Contribution of the H. pylori thiol peroxidase bacterioferritin comigratory protein to oxidative stress resistance and host colonisation. Infect. Immun. 73, 378-384 (2005). (Pubitemid 40041130)
152. Pflock M, Finsterer N, Joseph B, Mollenkopf H, Meyer TF, Beier D. Characterisation of the ArsRS regulon of H. pylori involved in acid adaptation. J. Bacteriol. 188, 3449-3462 (2006). (Pubitemid 43726208)
153. Dietz P, Gerlach G, Beier D. Identification of target genes regulated by the two-component system Hp0166-Hp0165 of H. pylori. J. Bacteriol. 184, 350-362 (2002). (Pubitemid 34027374)
154. Ge Z, Jiang Q, Kalisiak MS, Taylor DE. Cloning and functional characterisation of H. pylori fumarate reductase operon comprising three structural genes coding for subunits C, A and B. Gene. 204, 227-234 (1997). (Pubitemid 28022193)
155. Mendz GL, Hazell SH, Srinivasan S. Fumarate reductase: a target for therapeutic intervention against H. pylori. Arch. Biochem. Biophys. 321, 153-159 (1995).
156. Kim N, Marcus EA, Wen Y et al. Genes of H. pylori regulated by attachment to AGS cells. Infect. Immun. 72, 2358-2368 (2004). (Pubitemid 38419952)
157. Alamuri P, Maier RJ. Methionine sulphoxide reductase is an important antioxidant enzyme in the gastric pathogen H. pylori. Mol. Microbiol. 53, 1397-1406 (2004). (Pubitemid 39209113)
158. Tran AX, Karbarz MJ, Wang X et al. Periplasmic cleavage and modification of the 1-phosphate group of H. pylori lipid A. J. Biol. Chem. 279, 55780-55791 (2004). (Pubitemid 40066585)
159. Allan E, Dorrell N, Foynes S, Anyim M, Wren BW. Mutational analysis of genes encoding the early flagellar components of H. pylori: evidence for transcriptional regulation of flagellin A biosynthesis. J. Bacteriol. 182, 5274-5277 (2000). (Pubitemid 30700779)
160. Schoenhofen IC, Lunin VV, Julien JP et al. Structural and functional characterisation of PseC, an aminotransferase involved in the biosynthesis of pseudaminic acid, an essential flagellar modification in H. pylori. J. Biol. Chem. 281, 8907-8916 (2006). • Presents an example of an enzyme co-crystallized with its natural ligand and its functional characterization.
161. Pittman MS, Goodwin M, Kelly DJ. Chemotaxis in the human gastric pathogen H. pylori: different roles for CheW and the three CheV paralogues, and evidence for CheV2 phosphorylation. Microbiology 147, 2493-2504 (2001). (Pubitemid 32899245)
162. Foynes S, Dorrell N, Ward SJ et al. H. pylori possesses two CheY repsonse regulators and a histidine kinase sensor, CheA, which are essential for chemotaxis and colonisation of the gastric mucosa. Infect. Immun. 68, 2016-2023 (2000). (Pubitemid 30164832)
163. Terry K, Williams SM, Connolly L, Ottemann KM. Chemotaxis plays multiple roles during H. pylori animal infection. Infect. Immun. 73, 803-811 (2005). • The data elucidate the roles for chemotaxis in H. pylori mouse infections showing that genes involved in this function are candidate targets.
164. Jimenez-Pearson MA, Delany I, Scarlato V, Beier D. Phosphate flow in the chemotactic response system of H. pylori. Microbiology 151, 3299-3311 (2005). (Pubitemid 41488913)
165. Stingl K, Brandt S, Uhlemann EM et al. Channel-mediated potassium uptake in H. pylori is essential for gastric colonisation. EMBO J. 26, 232-241 (2007). (Pubitemid 46094714)
166. Schilling CH, Cover MW, Famili I, Church GM, Edwards JS, Palsson BO. Genome-scale metabolic model of H. pylori 26695. J. Bacteriol. 184, 4582-4593 (2002). (Pubitemid 34832586)
167. O'Rourke EJ, Chevalier C, Pinto AV et al. Pathogen DNA as a target for hostgenerated oxidative stress: role for repair of bacterial DNA damage in H. pylori colonisation. Proc. Natl Acad. Sci. USA 100, 2789-2794 (2003). (Pubitemid 36297577)
168. Hughes NJ, Clayton CL, Chalk PA, Kelly DJ. H. pylori porCDAB and oorDABC genes encode distinct pyruvate:flavodoxin and 2-oxoglutarate:acceptor oxidoreductases which mediate electron transport to NADP. J. Bacteriol. 180, 1119-1128 (1998).
169. Jeong JY, Mukhopadhyay AK, Dailidiene D et al. Sequential inactivation of rdxA (Hp0954) and frxA (Hp0642) nitroreductase genes causes moderate and high-level metronidazole resistance in H. pylori. J. Bacteriol. 182, 5082-5090 (2000).
170. Godlewska R, Pawlowski M, Dzwonek A et al. Tip-a (hp0596 gene product) is a highly immunogenic H. pylori protein involved in colonisation of mouse gastric mucosa. Curr. Microbiol. 56, 279-286 (2008).
171. Suganuma M, Yamaguchi K, Ono Y et al. TNF-α-inducing protein, a carcinogenic factor secreted from H. pylori, enters gastric cancer cells. Int. J. Cancer. 123, 117-122 (2008). (Pubitemid 351705199)
172. Spreng S, Gentaschev I, Goebel W et al. Identification of immunogenic antigens of H. pylori via the E. coli hemolysin secretion system. FEMS Microbiol. Lett. 186, 251-256 (2000). (Pubitemid 30232751)
173. Yan J, Liang SH, Mao YF, Li LW, Li SP. Construction of expression systems for flaA and flaB genes of H. pylori and determination of immunoreactivity and antigenicity of recombinant proteins. World J. Gastroenterol. 9, 2240-2250 (2003). (Pubitemid 37321453)
174. Suerbaum S, Josenhans C, Labigne A. Cloning and genetic characterisation of the H. pylori and H. mustelae flaB flagellin genes and construction of H. pylori flaA- and flaB-negative mutants by electroporation-mediated allelic exchange. J. Bacteriol. 175, 3278-3288 (1993). (Pubitemid 23163369)
175. Wang G, Alamuri P, Humayun MZ, Taylor DE, Maier RJ. The H. pylori MutS protein confers protection from oxidative DNA damage. Mol. Microbiol. 58(1), 166-176 (2005). (Pubitemid 41415038)
176. Wang G, Maier RJ. An NADPH quinone reductase of H. pylori plays an important role in oxidative stress resistance and host colonisation. Infect. Immun. 72, 1391-1396 (2004). (Pubitemid 38263760)
177. Kim H, Wu CA, Kim DY et al. Crystallisation and preliminary X-ray crystallographic study of UDP-glucose pyrophosphorylase (UGPase) from H. pylori. Acta Crystallogr. D Biol. Crystallogr. 60, 1447-1449 (2004). (Pubitemid 41079747)
178. Akada JK, Shirai M, Takeuchi H, Tsuda M, Nakazawa T. Identification of the urease operon in H. pylori and its control by mRNA decay in response to pH. Mol. Microbiol. 36, 1071-1084 (2000). (Pubitemid 30330679)
179. Ahn HJ, Yang JK, Lee BI, Yoon HJ, Kim HW, Suh SW. Crystallisation and preliminary X-ray crystallographic studies of chorismate synthase from H. pylori. Acta Crystallogr. D Biol. Crystallogr. 59, 569-571 (2003).
180. Ahn HJ, Yoon HJ, Lee BI, Suh SW. Crystal structure of chorismate synthase: a novel FMN-binding protein fold and functional insights. J. Mol. Biol. 336, 903-915 (2004).
181. Josenhans C, Eaton KA, Thevenot T, Suerbaum S. Switching of flagellar motility in H. pylori by reversible length variation of a short homopolymeric sequence repeat in fliP, a gene encoding a basal body protein. Infect. Immun. 68, 4598-4603 (2000). (Pubitemid 30497729)
182. Velayudhan J, Hughes NJ, McColm AA et al. Iron acquisition and virulence in H. pylori: a major role for FeoB, a high-affinity ferrous iron transporter. Mol. Microbiol. 37, 274-286 (2000). (Pubitemid 30481012)
183. Brahmachary P, Dashti MG, Olson JW, Hoover TR. H. pylori FlgR is an enhancerin-dependent activator of s54-RNA polymerase holoenzyme. J. Bacteriol. 186, 4535-4542 (2004).
184. Spohn G, Scarlato V. Motility of H. pylori is coordinately regulated by the transcriptional activator FlgR, an NtrC homolog. J. Bacteriol. 181, 593-599 (1999). (Pubitemid 29045152)
185. Fujinaga R, Nakazawa T, Shirai M. Allelic exchange mutagenesis of rpoN encoding RNA-polymerase s54 subunit in H. pylori. J. Infect. Chemother. 7, 148-155 (2001).
186. Niehus E, Gressmann H, Ye F et al. Genome-wide analysis of transcriptional hierarchy and feedback regulation in the flagellar system of H. pylori. Mol. Microbiol. 52, 947-961 (2004). (Pubitemid 38916167)
187. Duckworth M, Menard A, Megraud F, Mendz GL. Bioinformatic analysis of H. pylori XGPRTase: a potential therapeutic target. Helicobacter 11, 287-295 (2006). (Pubitemid 44051355)
188. Chen C, Ghosh S, Grove A. Substrate specificity of H. pylori histone-like HU protein is determined by insufficient stabilisation of DNA flexure points. Biochem. J. 383, 343-351 (2004). (Pubitemid 39446696)
189. Kim N, Weeks DL, Shin JM, Scott DR, Young MK, Sachs G. Proteins released by H. pylori in vitro. J. Bacteriol. 184, 6155-6162 (2002).
190. Kennedy DC, Herbst RW, Iwig JS, Chivers PT, Maroney MJ. A dynamic Zn site in H. pylori HypA: a potential mechanism for metal-specific protein activity. J. Am. Chem. Soc. 129, 1-17 (2007).
191. Olson JW, Mehta NS, Maier RJ. Requirement of nickel metabolism proteins HypA and HypB for full activity of both hydrogenase and urease in H. pylori. Mol. Microbiol. 39, 176-182 (2001).
192. Mehta N, Olson JW, Maier RJ. Characterisation of H. pylori nickel metabolism accessory proteins needed for maturation of both urease and hydrogenase. J. Bacteriol. 185, 726-734 (2003). (Pubitemid 36139432)
193. Harris AG, Wilson JE, Danon SJ, Dixon MF, Donegan K, Hazell SH. Catalase (KatA) and KatA-associated protein (KapA) are essential to persistent colonisation in the H. pylori SS1 mouse model. Microbiology 149, 665-672 (2003). (Pubitemid 36395101)
194. Loughlin MF, Barnard FM, Jenkins D, Sharples GJ, Jenks PJ. H. pylori mutants defective in RuvC Holliday junction resolvase display reduced macrophage survival and spontaneous clearance from the murine gastric mucosa. Infect. Immun. 71, 2022-2031 (2003). (Pubitemid 36368736)
195. 54 in H. pylori requires the novel protein Hp0958. J. Bacteriol. 187, 4463-4469 (2005).
196. Ryan KA, Karim N, Worku M, Moore SA, Penn CW, O'Toole PW. Hp0958 is an essential motility gene in H. pylori. FEMS Microbiol. Lett. 248, 47-55 (2005). (Pubitemid 40834313)
197. Gancz H, Censini S, Merrell DS. Iron and pH homeostasis intersect at the level of Fur regulation in the gastric pathogen H. pylori. Infect. Immun. 74, 602-614 (2006). (Pubitemid 43023116)
198. Bijlsma JJ, Waidner B, Vliet AH et al. The H. pylori homologue of the ferric uptake regulator is involved in acid resistance. Infect. Immun. 70, 606-611 (2002). (Pubitemid 34083819)
199. Bury-Mone S, Thiberge JM, Contreras M, Maitournam A, Labigne A, De Reuse H. Responsiveness of acidity via metal ion regulators mediates virulence in the gastric pathogen H. pylori. Mol. Microbiol. 53, 623-638 (2004). (Pubitemid 38998180)
200. Delany I, Ieva R, Soragni A, Hilleringmann M, Rappuoli R, Scarlato V. In vitro analysis of protein-operator interactions of the NikR and Fur metal-responsive regulators of coregulated genes in H. pylori. J. Bacteriol. 187, 7703-7715 (2005). (Pubitemid 41587709)
201. van Amsterdam K, van der Ende A. H. pylori Hp1034 (ylxH) is required for motility. Helicobacter. 9, 387-395 (2004).
202. Toscano MD, Stewart KA, Coggins JR, Lapthorn AJ, Abell C. Rational design of new bifunctional inhibitors of type II dehydroquinase. Org. Biomol. Chem. 3, 3102-3104 (2005). (Pubitemid 41374068)
203. Bottomley JR, Clayton CL, Chalk PA, Kleanthous C. Cloning, sequencing, expression, purification and preliminary characterisation of a type II dehydroquinase from H. pylori. Biochem. J. 319, 559-565 (1996). (Pubitemid 26372217)
204. Lee BI, Kwak JE, Suh SW. Crystal structure of the type II 3-dehydroquinase from H. pylori. Protein. 51, 616-617 (2003).
205. Sanchez-Sixto C, Prazeres VFV, Castedo L et al. Competitive inhibitors of H. pylori type II dehydroquinase: synthesis, biological evaluation, and NMR studies. Chem. Med. Chem. 3, 756-770 (2008).
206. McGee DJ, Langford ML, Watson EL, Carter JE, Chen YT, Ottemann KM. Colonisation and inflammation deficiencies in Mongolian gerbils infected by H. pylori chemotaxis mutants. Infect. Immun. 73, 1820-1827 (2005). • Clarifies the role of a chemoreceptor in the inflammatory response to H. pylori and of a chemotaxis regulator in initial colonization.
207. Beier D, Spohn G, Rappuoli R, Scarlato V. Identification and characterisation of an operon of H. pylori that is involved in motility and stress adaptation. J. Bacteriol. 179, 4676-4683 (1997). (Pubitemid 27339710)
208. Wolfram L, Bauerfeind P. Conserved low-affinity nickel-binding amino acids are essential for the function of the nickel permease NixA of H. pylori. J. Bacteriol. 184, 1438-1443 (2002). (Pubitemid 34157568)
209. Fulkerson JF Jr, Garner RM, Mobley HLT. Conserved residues and motifs in the NixA protein of H. pylori are critical for the high affinity transport of nickel ions. J. Biol. Chem. 273, 235-241 (1998).
210. Hendricks JK, Mobley HLT. H. pylori ABC transporter: effect of allelic exchange mutagenesis on urease activity. J. Bacteriol. 179, 5892-5902 (1997).
211. Fulkerson JF Jr, Mobley HLT. Membrane topology of the NixA nickel transporter of H. pylori: two nickel tranport-specific motifs within transmembrane helices II and III. J. Bacteriol. 182, 1722-1730 (2000).
212. Nolan KJ, McGee DJ, Mitchell HM et al. In vivo behaviour of a H. pylori SS1 nixA mutant with reduced urease activity. Infect. Immun. 70, 685-691 (2002).
213. Burns BP, Mendz GL, Hazell SL. In situ properties of H. pylori aspartate carbamoyltransferase. Arch. Biochem. Biophys. 347, 119-125 (1997).
214. Burns BP, Hazell SL, Mendz GL, Kolesnikow T, Tillet D, Neilan BA. The H. pylori pyrB gene encoding aspartate carbamoyltransferase is essential for bacterial survival. Arch. Biochem. Biophys. 380, 78-84 (2000). (Pubitemid 30616773)
215. Wanken AE, Conway T, Eaton KA. The entner-doudoroff pathway has little effect on H. pylori colonisation of mice. Infect. Immun. 71, 2920-2923 (2003). (Pubitemid 36519910)
216. Hughes NJ, Chalk PA, Clayton CL, Kelly DJ. Identification of carboxylation enzymes and characterisation of a novel four-subunit pyruvate:flavodoxin oxidoreductase from H. pylori. J. Bacteriol. 177, 3953-3959 (1995).
217. Hoffman PS, Sisson G, Croxen MA et al. Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductase of H. pylori and selected anaerobic bacteria and parasites, and C. jejuni. Antimicrob. Agents Chemother. 51, 868-876 (2006).
218. Guttner Y, Windsor HM, Viiala CH, Dusci L, Marshall BJ. Nitazoxanide in treatment of H. pylori: a clinical and in vitro study. Antimicrob. Agents Chemother. 47, 3780-3783 (2003). (Pubitemid 37484988)
219. Megraud F, Occhialini A, Rossignol JF. Nitazoxanide, a potential drug to eradicate H. pylori with no cross resistance to metronidazole. Antimicrob. Agents Chemother. 42, 2836-2840 (1998). (Pubitemid 28501212)
220. McGovern KJ, Blanchard TG, Gutierrez JA, Czinn SJ, Krakowka S, Youngman P. γ-glutamyltransferase is a H. pylori virulence factor but is not essential for colonisation. Infect. Immun. 69, 4168-4173 (2001). (Pubitemid 32493346)
221. Chevalier C, Thiberge JM, Ferrero RL, Labigne A. Essential role of H. pylori γ-glutamyltranspeptidase for the colonisation of the gastric mucosa of mice. Mol. Microbiol. 31, 1359-1372 (1999). (Pubitemid 29110095)
222. Kim K, Lee S, Park M et al. γ-glutamyltranspeptidase of H. pylori induces mitochondria-mediated apoptosis in AGS cells. Biochem. Biophys. Res. Commun. 355, 562-567 (2007). (Pubitemid 46282663)
223. Morrow AL, Williams K, Sand A, Boanca G, Barycki JJ. Characterisation of H. pylori γ-glutamyltranspeptidase reveals the molecular basis for substrate specificity and a critical role for the tyrosine 433-containing loop in catalysis. Biochemistry 46, 13407-13414 (2007). (Pubitemid 350136379)
224. Cremades N, Velazquez-Campoy A, Freire E, Sancho J. The flavodoxin from H. pylori: structural determinants of thermostability and FMN cofactor binding. Biochemistry 47, 627-639 (2007). (Pubitemid 351195434)
225. St Maurice M, Cremades N, Croxen MA, Sisson G, Sancho J, Hoffman PS. Flavodoxin:quinone reductase (FqrB): a redox partner of pyruvate:ferredoxin oxidoreductase that reversibly couples pyruvate oxidation ot NADPH production in H. pylori and C. jejuni. J. Bacteriol. 189, 4764-4773 (2007). (Pubitemid 47025588)
226. Psakis G, Polaczek J, Essen LO et al. Obstinate contaminants in a picrogram scale. One more bottleneck in the membrane protein structure pipeline. J. Struct. Biol. 166. 107-111 (2009).
227. Chiu HC, Lin TL, Wang JT. Identification and characterisation of an organic solvent tolerance gene in H. pylori. Helicobacter 12, 74-81 (2007).
228. Ye S, Von Delft F, Brooun A, Knuth MW, Swanson RV, McRee DE. The crystal structure of shikimate dehydrogenase (AroE) reveals a unique NADPH binding mode. J. Bacteriol. 185, 4144-4151 (2003). (Pubitemid 36835254)
229. Hurdle JG, O'Neill AJ, Chopra I. Prospects for aminoacyl-tRNA synthetase inhibitors as new antimicrobial agents. Antimicrob Agents Chemother. 49, 4821-4833 (2005). (Pubitemid 41778891)
230. Kanamaru T, Nakano Y, Toyoda Y et al. In vitro and in vivo antibacterial activities of TAK-083, an agent for treatment of H. pylori infection. Antimicrob. Agents Chemother. 45, 2455-2459 (2001). (Pubitemid 32801895)
231. Werner RG, Thorpe LF, Reuter W, Nierhaus KH. Indolmycin inhibits prokaryotic tryptophanyl-tRNA ligase. Eur. J. Biochem. 68, 1-3 (1976).
232. Kim S, Lee SW, Choi EC, Choi SY. Aminoacyl-tRNA synthetases and their inhibitors as a novel family of antibiotics. Appl. Microbiol. Biotechnol. 61, 278-288 (2003). (Pubitemid 36683523)
233. Kim MK, Song HE, Kim YS et al. Crystallisation and preliminary X-ray crystallographic analysis of orotate phosphoribosyltransferase from H. pylori. Mol. Cell. 15, 361-363 (2003).
234. Loh JT, Clover TL. Requirement of hisitine kinases Hp0165 and Hp1364 for acid resistance in H. pylori. Infect. Immun. 74, 3052-3059 (2006).
235. Pflock M, Muller S, Beier D. The CrdRS (Hp1365-Hp1364) two-component system is not involved in pH-responsive gene regulation in the H. pylori strains 26695 and G27. Curr. Microbiol. 54, 320-324 (2007). (Pubitemid 46452247)
236. Lee B, Lee JY, Moon J, Han BW, Suh SW. Crystallisation and preliminary X-ray crystallographic analysis of UDP-N-aceylglucosamine acyltransferase from H. pylori. Acta Crystallogr. D. Biol. Crystallogr. 58, 864-866 (2002). (Pubitemid 34557304)
237. Lee B, Suh SW. Crystal structure of UDP-N-acetylglucosamine acyltransferase from H. pylori. Proteins 53, 772-774 (2003).
238. Wang G, Maier RJ. Critical role of RecN in recombinational DNA repair and survival of H. pylori. Infect. Immun. 76, 153-160 (2008). • Identifies H. pylori RecN as a component of DNA recombinational repair that plays a significant role in survival of the bacterium in vivo.
239. Porwollik S, Noonan B, O'Toole PW. Molecular characterisation of a flagellar export locus of H. pylori. Infect. Immun. 67, 2060-2070 (1999). (Pubitemid 29200453)
240. Zhang ZW, Dorrell N, Wren BW, Farthing MJG. H. pylori adherence to gastric epithelial cells: a role for non-adhesin virulence genes. J. Med. Microbiol. 52, 495-502 (2002). (Pubitemid 34492978)
241. Jenks PJ, Foynes S, Ward SJ, Constantinidou C, Penn CW, Wren BW. A flagellar-specific ATPase (FliI) is necessary for flagellar export in H. pylori. FEMS Microbiol. Lett. 152, 205-211 (1997). (Pubitemid 27316685)
242. Lane MC, O'Toole PW, Moore SA. Molecular basis of the interaction between the flagellar export proteins FliI and FliH from H. pylori. J. Biol Chem. 281, 508-517 (2006).
243. Karnholz A, Hoefler C, Odenbreit S, Fischer W, Hofreuter D, Haas R. Functional and topologicl characterisation of novel components of the comB DNA transformation competence system in H. pylori. J. Bacteriol. 188, 882-893 (2006). (Pubitemid 43146403)
244. Barnard FM, Loughlin MF, Fainberg HP et al. Global regulation of virulence and the stress response by CsrA in the highly adapted human gastric pathogen H. pylori. Mol. Microbiol. 51, 15-32 (2004).
245. + antiporter (NhaA) protein from H. pylori required for ion transport and pH sensing. J. Biol. Chem. 278, 21467-21473 (2003).
246. + antiporter NhaA faces a water-filled channel required for ion transport. J. Biol. Chem. 279, 40567-40575 (2004).
247. + antiporter of H. pylori from partial fragments in vivo. Biochemistry 46, 14272-14283 (2007).
248. Papinutto E, Windle HJ, Cendron L, Battistutta R, Kelleher D, Zanotti G. Crystal structure of alkyl hydroperoxide-reductase (AhpC) from H. pylori. Biochim. Biophys. Acta - Proteins and Proteomics 1753, 240-246 (2005). (Pubitemid 41643157)
249. Jenks PJ, Chevalier C, Ecobichon C, Labigne A. Identification of nonessential H. pylori genes using random mutagenesis and loop amplification. Res. Microbiol. 152, 725-734 (2001). (Pubitemid 32905505)